Medicines Australia's decision to moderate its celebratory tone on the HTA Review options paper should be welcomed, but the communication needs to go beyond its members, and it needs to stop pushing for a response in the 2024-25 Budget. …
If this is the real view, then the onus is on the association to share it more broadly
February 19, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Nyrada commences recruitment for phase one clinical trial
March 17, 2025 - -
Neurizon Therapeutics updates investors on initiatives to lift clinical hold
March 17, 2025 - - Australian Biotech -
Radiopharm Theranostics says new data confirms positive tumour uptake
March 17, 2025 - - Australian Biotech -
Race secures ethics approval for RC220 Phase 1 solid tumour trial
March 17, 2025 - - Australian Biotech -
TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer
March 17, 2025 - - Latest News -
Doctor group changes position on weight-loss therapies and the PBS
March 17, 2025 - - Latest News -
In 2025, the US is more likely to adopt PBS pricing policies than oppose them
March 17, 2025 - - Latest News